NCT01171989 - Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose | Biotech Hunter

Enrollment

391

Participants

Timeline

Start Date

August 18, 2010

Primary Completion Date

December 3, 2010

Study Completion Date

December 3, 2010

Conditions

TetanusDiphtheriaHaemophilus Influenzae Type bHepatitis BPoliomyelitisAcellular PertussisDiphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b-Neisseria Meni

Interventions

BIOLOGICAL

GSK2202083A vaccine

Intramuscular, one dose.

BIOLOGICAL

Infanrix hexa™

Intramuscular, one dose.

BIOLOGICAL

Menjugate™

Intramuscular, one dose.

BIOLOGICAL

NeisVac-C™

Intramuscular, one dose.

BIOLOGICAL

Synflorix™

Intramuscular, one dose.

Trial Locations (9)

50345

GSK Investigational Site, Wroclaw

85-021

GSK Investigational Site, Bydgoszcz

39-200

GSK Investigational Site, Dębica

31-422

GSK Investigational Site, Krakow

31-503

GSK Investigational Site, Krakow

41-103

GSK Investigational Site, Siemianowice Śląskie

33-100

GSK Investigational Site, Tarnów

Unknown

GSK Investigational Site, Torun

55-100

GSK Investigational Site, Trzebnica